<- Go Home
Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Market Cap
$73.7M
Volume
243.3K
Cash and Equivalents
$84.8M
EBITDA
-$32.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.75
52 Week Low
$0.77
Dividend
N/A
Price / Book Value
0.73
Price / Earnings
-1.14
Price / Tangible Book Value
0.73
Enterprise Value
-$10.9M
Enterprise Value / EBITDA
0.33
Operating Income
-$32.5M
Return on Equity
58.98%
Return on Assets
-37.22
Cash and Short Term Investments
$84.8M
Debt
$244.4K
Equity
$83.9M
Revenue
N/A
Unlevered FCF
-$36.6M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium